APVO
Aptevo Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.37
+0.74%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.35
From 52W high−95.12%
Volume14715.00
Market cap$2.48M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.35
From 52W high
−95.12%
Volume
14715.00
Market cap
$2.48M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
27.5
MomentumView details →
1D Return
+0.74%
YTD Return
−85.88%
SummaryUpdated Jun 1, 2026
Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Seattle, Washington. The company emerged as a spinoff focused on developing innovative immunotherapeutic treatments for various forms of cancer. Aptevo specializes in creating bispecific antibodies, which are engineered proteins designed to simultaneously target two different antigens to enhance the body's immune response against cancer cells. The company has developed proprietary platform technologies called ADAPTIR and ADAPTIR-FLEX to create these specialized therapeutic candidates.
Similar companies
Latest newsMore news →
Aptevo Therapeutics Inc. amended its rights agreement with Broadridge Corporate Issuer Solutions, LLC, extending the final expiration date to October 23, 2027 and setting the purchase price at $14.56 per one one-thousandth of a preferred share.12d agoAptevo Therapeutics announced progress in its next-generation trispecific immuno-oncology programs, optimizing several trispecific candidates for scalable manufacturing ahead of future human testing.41d agoAptevo Therapeutics announced clinical trial results for its lead candidate mipletamig, reporting a 93% clinical benefit rate in frontline acute myeloid leukemia patients with TP53 mutations.62d ago